Healthcare Realty Posts Its Best Leasing Spreads in a Decade. The Stock Is Down 15% From July.
A third guidance raise, 8.6% cash spreads, and a share price that says the market is pricing the bond market, not the buildings.
HR · Earnings Call · 2026-10-30
The quarter that should have worked
Healthcare Realty opened its third-quarter call with the kind of numbers a medical-office landlord has not printed in years: normalized FFO of $0.42, same-store NOI up 5.1%, occupancy at 93.1%, and cash leasing spreads of 8.6% — which COO Rob Hull described as “the highest level for the company in nearly a decade” — Rob Hull, Chief Operating Officer or Operations Executive · 2026-10-30. Management raised full-year FFO guidance to $1.65–$1.67 and lifted same-store NOI growth to 5%–5.25%. That is the third raise of the year, and the second consecutive two-penny bump at the midpoint. And the stock is still down roughly 9% over the last 90 trading days, 15.5% off its late-July peak near $21.87. Pete Scott did not pretend otherwise: “Higher interest rates have weighed on real estate stocks, including ours, but not on our fundamentals.” — Pete Scott, Chief Executive Officer or President · 2026-10-30 That sentence is the whole dossier. The global keyword tape confirms the macro side of it — Fed rate hike was the second-highest-momentum theme in the entire market this quarter, with impact of high rates also ranking in the top fifteen. HR is a levered, long-duration cash-flow stream whose operating story is accelerating while its discount rate is not cooperating.Pricing power enters the vocabulary
The freshest thing in this transcript is a change in how management describes its own leverage. Pricing power is a brand-new top-ranked keyword for HR this quarter — it has not led the company's keyword set before, and Scott leans on it repeatedly: “3% is now the floor, not the ceiling” — Pete Scott, Chief Executive Officer or President · 2026-10-30 on escalators, with select deals pushing toward 4% when HR contributes capital. Retention is running at 88%, and roughly 480,000 square feet of signed-not-occupied space sits in the pipeline. This is a real, measurable operating shift rather than rhetoric. The revamped leasing model — economics-driven rather than volume-driven, introduced about eighteen months ago — is now quantified: lease IRRs up nearly 3,000 basis points and payback periods down 25%. The mark-to-market story has also moved from adjectives to a range. On the October 2025 call, Scott told investors HR had been achieving “kind of the low single digits” — Peter Scott, President and CEO · 2025-10-31 on mark-to-market. This quarter he put it at mid-single digits or better. Add the site-of-care shift — the inpatient-only list shrinking, Ascension Saint Thomas buying AMSURG, Bon Secours bidding for Surgery Partners — and you get the structural argument for outpatient setting demand that HR has been making for several calls, now with rent checks attached. Note what has quietly receded. The strategic plan stump speech — the three-year framework, the multiple-rerating argument, the "success for us is not going from an 11x FFO multiple to a 30x" sermon from the May call — is largely gone. So is earnings growth as the headline framing. What replaced it is narrower and more credible: leasing economics, escalators, retention. When a CEO stops selling the destination and starts selling the mileage, that is usually a sign of confidence, or of a share price that has stopped paying for vision.What the beats are hiding
The tension sits in the fourth quarter and in the second year. Guidance implies $0.40–$0.42 of FFO in Q4, and same-store NOI growth decelerates — not because the business is cracking, but because the occupancy tailwind is annualizing against a hard comp. “I would just say that we are not forecasting as much absorption” — Pete Scott, Chief Executive Officer or President · 2026-10-30, Scott conceded. Three percent contractual escalators plus mid-single-digit spreads gets you 3%–4% NOI growth on a stabilized basis; everything above that this year has come from absorption. The other soft spot is timing. CFO Dan Gabbay was explicit that the recapture of lost NOI from the redevelopment and lease-up portfolios is “more backend weighted” — Dan Gabbay, Chief Financial Officer or Finance Executive · 2026-10-30 — HR targets recapturing $40 million of the $50 million lost post-merger, with most of the benefit landing in 2027 and 2028. That is why backend weighted shows up as a new keyword this quarter. It is honest, but it is also a deferral. Then there is the gap between the FFO story and the GAAP story. The last filed quarter shows net income of -$44 million and a net margin of roughly -15.6%, while interest coverage sits at 1.4x, down 27% over two years. The offset is the balance sheet work: interest expense has fallen 15% year-on-year to $45 million after refinancing $1.1 billion at a blended ~4%, with leverage at 5.5x and $1.2 billion of line capacity plus a $400 million delayed draw backstopping the July 2027 maturity. HR is not a credit story — but it is a company whose equity is priced off rates it cannot control.Capital allocation: the arb widens, then narrows
The most instructive reversal this quarter is in buybacks. On the July call, Scott said the relative attractiveness of repurchases had changed and that— the stock had rerated. One quarter later HR bought $75 million of stock at a weighted average of $17.74, an FFO yield above 9%, bringing the year-to-date total to $250 million. The underwriting is mechanical: when the shares trade at “a pretty significant discount to NAV” — Pete Scott, Chief Executive Officer or President · 2026-10-30, buy the shares; when they do not, write JV checks. That joint venture acquisition channel is now a genuine second engine — eight buildings acquired year-to-date for $338 million, or $67 million at HR's share, at a mid-7% initial cash yield to HR, against core-plus cap rates of 6%–6.5%. The arbitrage works because HR is selling into a deep private bid. Which brings up the quietly important new keyword weaker assets: cap rates are holding in core and core-plus, but value-add buyers are leverage-dependent, and leverage is expensive. HR's portfolio is on the right side of that bifurcation — and the private buyers know it. The bear case is not that HR is wrong about medical office. It is that everything management can control — spreads, retention, escalators, capital recycling — is already working, and the shares still fell this quarter. Until the rate regime turns, the story is a company compounding into a valuation it cannot argue its way out of.at the moment, you know, I think buybacks do not screen as favorably